Navigation Links
Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011

OMAHA, Neb., March 8, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) today announced the following Webcast:What:

Transgenomic, Inc. Fourth Quarter 2010 Financial Results and Business Update Conference CallWhen:

Friday, March 11, 2011 @ 11:00 a.m. EasternWhere:

Live over the Internet -- Simply log on to the web at the address above.Contact:

Investor Relations, 402-452-5400 To access the call via telephone, call 800-895-1715 from the U.S. or Canada or 785-424-1059 for international participants and enter conference ID TRANS.  A telephone replay will be available from 1:00 p.m. Eastern Time March 11, 2011 through 11:59 p.m. Eastern Time on March 25, 2011 by dialing 800-723-0528 (domestic) or 402-220-2654 (international).

About Transgenomic, Inc.Transgenomic, Inc. ( ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification.  With broad applicability to genetic research, nearly 1,500 systems have been shipped to customers in more than 50 countries. The SURVEYOR® Mutation Detection Kits provide reagents and protocols for high sensitivity detection of mutations in DNA.  HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.  In December of 2010, we acquired another CLIA certified laboratory in New Haven, Connecticut which specializes in genetic disorders associated with cardiomyopathies and channelopathies.  We believe there is a significant opportunity for us to continue growing the demand for molecular-based testing by leveraging our technologies, experience and expertise in biomarker analysis. In addition, we continue to seek out and evaluate new technologies and new laboratory tests which will further extend our offerings in our Molecular Diagnostics Laboratory and our Pharmacogenomics Services Lab.


SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
2. Transgenomic Reports Third Quarter Financial Results
3. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
4. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
5. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
6. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
7. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
8. Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
9. Transgenomic Presents at 12th Annual BIO CEO & Investor Conference
10. Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit
11. Transgenomic, Inc. Reports Third Quarter 2009 Results
Post Your Comments:
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):